KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Current Leases (2019 - 2025)

Pacific Biosciences Of California (PACB) has 7 years of Current Leases data on record, last reported at $448000.0 in Q4 2025.

  • For Q4 2025, Current Leases fell 95.53% year-over-year to $448000.0; the TTM value through Dec 2025 reached $448000.0, down 95.53%, while the annual FY2025 figure was $448000.0, 95.53% down from the prior year.
  • Current Leases reached $448000.0 in Q4 2025 per PACB's latest filing, down from $621000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $12.5 million in Q2 2024 and bottomed at $448000.0 in Q4 2025.
  • Average Current Leases over 5 years is $7.1 million, with a median of $8.5 million recorded in 2022.
  • Peak YoY movement for Current Leases: skyrocketed 81.12% in 2022, then crashed 95.53% in 2025.
  • A 5-year view of Current Leases shows it stood at $7.7 million in 2021, then grew by 15.25% to $8.9 million in 2022, then increased by 7.93% to $9.6 million in 2023, then increased by 4.54% to $10.0 million in 2024, then plummeted by 95.53% to $448000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $448000.0 in Q4 2025, $621000.0 in Q3 2025, and $703000.0 in Q2 2025.